{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:53:43Z","timestamp":1790466823074,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["The NeoALTTO study was sponsored by GlaxoSmithKline from its inception until November 30, 2015, and by Novartis since then. Lapatinib is an asset of Novartis AG as of March 2, 2015. Funding sources had no involvement in study design, data collection, analysis and interpretation, writing of the report, and decision to submit the article for publication."],"award-info":[{"award-number":["The NeoALTTO study was sponsored by GlaxoSmithKline from its inception until November 30, 2015, and by Novartis since then. Lapatinib is an asset of Novartis AG as of March 2, 2015. Funding sources had no involvement in study design, data collection, analysis and interpretation, writing of the report, and decision to submit the article for publication."]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Obesity is a risk factor for breast cancer (BC) development, recurrence, and death. In view of this, we aimed to investigate the clinical value of obesity in BC patients treated with anti-HER2 therapies in the NeoALTTO trial, which randomized 455 patients to neo-adjuvant lapatinib, trastuzumab, or their combination plus paclitaxel.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients were classified according to their basal body mass index (BMI) into underweight (&lt;\u200918.5\u2009kg\/m<jats:sup>2<\/jats:sup>), normal (\u2265\u200918.5; &lt;\u200925\u2009kg\/m<jats:sup>2<\/jats:sup>), overweight (\u2265\u200925; &lt;\u200930\u2009kg\/m<jats:sup>2<\/jats:sup>), and obese (\u2265\u200930\u2009kg\/m<jats:sup>2<\/jats:sup>) WHO categories. Univariate and multivariate logistic regression analyses were performed using BMI as a categorical variable. Pathological complete response (pCR) and event-free survival (EFS) were the NeoALTTO primary and secondary outcomes, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 454 patients analyzed, 14 (3%), 220 (48%), 137 (30%), and 83 (18%) were classified as underweight, normal weight, overweight, and obese, respectively; 231 (51%) and 223 (49%) had hormone receptor (HR)-positive and HR-negative primary tumors; 160 (35%) achieved pCR. In the overall patient population, no association was found between BMI groups and pCR, as we reported pCR rates of 57.1%, 35%, 30.7%, and 39.8% in underweight, normal weight, overweight, and obese cases, respectively. In contrast, in HR-positive tumors, overweight or obesity was generally associated with decreased likelihood of achieving a pCR independently of other clinical variables, including planned surgery, nodal status, and tumor size (odds ratio [OR]\u2009=\u20090.55, 95%CI 0.30\u20131.01, as compared to normal or underweight; <jats:italic>p<\/jats:italic>\u00a0=\u20090.053); notably, no differential effect of BMI with respect to pCR was observed in HR-negative cases (odds ratio [OR]\u2009=\u20091.30, 95%CI 0.76\u20132.23, as compared to normal or underweight; <jats:italic>p<\/jats:italic>\u00a0=\u20090.331), resulting in a statistically significant interaction between BMI and HR status (<jats:italic>p<\/jats:italic>\u00a0=\u20090.036). There was no association between BMI and EFS neither in the overall nor in the HR-positive population, but this analysis was under-powered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>NeoALTTO patients overweight or obese at baseline and with HR-positive primary BC appeared less likely to achieve pCR after neo-adjuvant anti-HER2 therapies. This finding paves the way to future research in targeting the interplay between HER2\/HR signaling and metabolism.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-020-01356-w","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T10:04:01Z","timestamp":1603793041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Serena","family":"Di Cosimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Porcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Agbor-tarh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice","family":"Franzoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmen","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Daidone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"1356_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1158\/0008-5472.CAN-09-2257","volume":"70","author":"KA Brown","year":"2010","unstructured":"Brown KA, Simpson ER. Obesity and breast cancer: progress to understanding the relationship. Cancer Res. 2010;70:4.","journal-title":"Cancer Res"},{"key":"1356_CR2","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","volume":"25","author":"DSM Chan","year":"2014","unstructured":"Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer\u2014systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25:1901\u201314.","journal-title":"Ann Oncol"},{"key":"1356_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-015-3287-5","volume":"150","author":"C Fontanella","year":"2015","unstructured":"Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat. 2015;150:127\u201339.","journal-title":"Breast Cancer Res Treat"},{"key":"1356_CR4","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/cncr.28051","volume":"119","author":"JA Crozier","year":"2013","unstructured":"Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer. 2013;119:2447\u201354.","journal-title":"Cancer"},{"key":"1356_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041380","volume":"7","author":"S Chen","year":"2012","unstructured":"Chen S, Chen C-M, Zhou Y, Zhou R-J, Yu K-D, Shao Z-M. Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer. PLoS One. 2012;7:e41380.","journal-title":"PLoS One"},{"key":"1356_CR6","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1200\/JCO.2007.14.4527","volume":"26","author":"JK Litton","year":"2008","unstructured":"Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau S-W, Bondy M, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. JCO Am Soc Clin Oncol. 2008;26:4072\u20137.","journal-title":"JCO Am Soc Clin Oncol"},{"key":"1356_CR7","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1634\/theoncologist.2012-0169","volume":"17","author":"E Del Fabbro","year":"2012","unstructured":"Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17:1240\u20135.","journal-title":"Oncologist"},{"key":"1356_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","volume":"379","author":"J Baselga","year":"2012","unstructured":"Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633\u201340.","journal-title":"Lancet"},{"key":"1356_CR9","unstructured":"World Health Organization - Nutrition - Body mass index classification. 2020. Available from: https:\/\/www.euro.who.int\/en\/health-topics\/disease-prevention\/nutrition\/a-healthy-lifestyle\/body-mass-index-bmi."},{"key":"1356_CR10","doi-asserted-by":"publisher","first-page":"6360","DOI":"10.1158\/1078-0432.CCR-13-0916","volume":"19","author":"A Bardia","year":"2013","unstructured":"Bardia A, Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res. 2013;19:6360.","journal-title":"Clin Cancer Res"},{"key":"1356_CR11","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1200\/JCO.2016.68.4480","volume":"34","author":"S Jiralerspong","year":"2016","unstructured":"Jiralerspong S, Goodwin PJ. Obesity and breast cancer prognosis: evidence, challenges, and opportunities. JCO. Am Soc Clin Oncol. 2016;34:4203\u201316.","journal-title":"JCO. Am Soc Clin Oncol"},{"key":"1356_CR12","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1007\/s00268-010-0683-1","volume":"34","author":"SPL Leong","year":"2010","unstructured":"Leong SPL, Shen Z-Z, Liu T-J, Agarwal G, Tajima T, Paik N-S, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34:2308\u201324.","journal-title":"World J Surg"},{"key":"1356_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-014-3091-7","volume":"147","author":"SJ Ioannides","year":"2014","unstructured":"Ioannides SJ, Barlow PL, Elwood JM, Porter D. Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review. Breast Cancer Res Treat. 2014;147:237\u201348.","journal-title":"Breast Cancer Res Treat"},{"key":"1356_CR14","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.5301\/tj.5000515","volume":"102","author":"A Gevorgyan","year":"2016","unstructured":"Gevorgyan A, Bregni G, Galli G, Ganzinelli M, Martinetti A, Lo Vullo S, et al. Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer. Tumori. 2016;102:e11\u20134.","journal-title":"Tumori"},{"key":"1356_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/obr.12281","volume":"16","author":"S Schmidt","year":"2015","unstructured":"Schmidt S, Monk JM, Robinson LE, Mourtzakis M. The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: potential effects of exercise. Obes Rev. 2015;16:473\u201387.","journal-title":"Obes Rev"},{"key":"1356_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/157339912799424519","volume":"8","author":"L Vona-Davis","year":"2012","unstructured":"Vona-Davis L, Rose DP. Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy. Current Diabetes Reviews. 2012;8:116\u201330.","journal-title":"Current Diabetes Reviews"},{"key":"1356_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fendo.2015.00012","volume":"6","author":"TB Salisbury","year":"2015","unstructured":"Salisbury TB, Tomblin JK. Insulin\/Insulin-like growth factors in cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and new blocking strategies. Front Endocrinol (Lausanne). 2015;6:12.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1356_CR18","first-page":"538019","volume":"2015","author":"VP Brahmkhatri","year":"2015","unstructured":"Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-like growth factor system in cancer. Novel Targeted Therapies. 2015;2015:538019.","journal-title":"Novel Targeted Therapies"},{"key":"1356_CR19","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.3892\/ijo.2017.3976","volume":"50","author":"MSJ McDermott","year":"2017","unstructured":"McDermott MSJ, Canonici A, Ivers L, Browne BC, Madden SF, O\u2019Brien NA, et al. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells. Int J Oncol. 2017;50:2221\u20138.","journal-title":"Int J Oncol"},{"key":"1356_CR20","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1158\/1078-0432.CCR-15-0574","volume":"23","author":"MM Reinholz","year":"2017","unstructured":"Reinholz MM, Chen B, Dueck AC, Tenner K, Ballman K, Riehle D, et al. IGF1R protein expression is not associated with differential benefit to concurrent trastuzumab in early-stage HER2(+) breast cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. Clin Cancer Res. 2017;23:4203\u201311.","journal-title":"Clin Cancer Res"},{"key":"1356_CR21","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/cncr.27466","volume":"118","author":"W Demark-Wahnefried","year":"2012","unstructured":"Demark-Wahnefried W, Campbell KL, Hayes SC. Weight management and its role in breast cancer rehabilitation. Cancer. 2012;118:2277\u201387.","journal-title":"Cancer."},{"key":"1356_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/1758834016665077","volume":"8","author":"L Lousberg","year":"2016","unstructured":"Lousberg L, Collignon J, Jerusalem G. Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol. 2016;8:429\u201349.","journal-title":"Ther Adv Med Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01356-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-020-01356-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01356-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T23:34:22Z","timestamp":1635291262000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-020-01356-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1186\/s13058-020-01356-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"10 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The NeoALTTO trial (Breast International Group 01-06) is a randomized, multicenter, open-label, phase 3 study. From Jan 5, 2008, to May 27, 2010, 455 patients entered the study from 86 sites in 23 countries in Europe, Asia, North and South America, and South Africa. The ethics committee and relevant health authorities at each participating institution approved the study protocol. All women gave written informed consent before study entry.Patients\u2019 participation in this sub-study was allowed after signing the main study consent form, which included a non-specific clause for use of clinical data for secondary analyses.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not include any individual person\u2019s details, so patient consent for publication is not applicable in this case. All authors listed and the NeoALTTO steering committee approved the present manuscript and consented for its publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SDC reports honoraria and advisory board from Novartis and Pierre-Fabre outside the scope of this work. DF received support for his Institution from GlaxoSmithKline until November 30, 2015, and from Novartis since then for the conduction of the NeoALTTO study, from AstraZeneca, Pfizer, Roche\/Genentech, Servier, and Tesaro outside the submitted work. EdA reports honoraria and advisory board from Roche\/GNE, Novartis, and Seattle Genetics; travel grants from Roche\/GNE and GSK\/Novartis; and research grant to his institution from Roche\/GNE, Astra-Zeneca, GSK\/Novartis, and Servier. CS, MAF, LP, DAT, SC, MCS, and MGD have no conflicts of interest to declare. HJ received honoraria from Roche, Novartis; advisory board from Roche, Novartis; and travel support from Roche, Novartis. MI is an employee of Novartis and has stock or other ownership: Novartis. MP declared the following: Board Member (Scientific Board): Oncolytics, Radius; Consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Oncolytics, Periphagen, Pfizer, Roche, Seattle Genetics; research grants to her institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon; MGD has no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}